Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Interaction between Doxorubicin and the Resistance Modifier Stilbene on Multidrug Resistant Mouse Lymphoma and Human Breast Cancer Cells

MARIA-JOSÉ U. FERREIRA, NOÉLIA DUARTE, NORA GYÉMÁNT, RITA RADICS, GEORGY CHEREPNEV, ANDRAS VARGA and JOSEPH MOLNÁR
Anticancer Research September 2006, 26 (5A) 3541-3546;
MARIA-JOSÉ U. FERREIRA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NOÉLIA DUARTE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NORA GYÉMÁNT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
RITA RADICS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GEORGY CHEREPNEV
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANDRAS VARGA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JOSEPH MOLNÁR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: molnarj{at}comser.szote.u-szeged.hu
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

The hydroxystilbene trans-3,5,3′,4′-tetrahydroxystilbene (piceatannol) (1), isolated from the methanol extract of Euphorbia lagascae defatted seeds, was methylated to yield the derivatives trans-3,5,3′,4′-tetramethoxystilbene (2), (trans-3,5-dihydroxy-3′,4′-dimethoxystilbene) (3) and trans-3,5,3′-trihydroxy-4′-methoxystilbene (4). The structures of the compounds were assigned by spectroscopic methods (IR, 1H-NMR, 13C-NMR and MS). The ability of piceatannol (1) and the three methylated derivatives to modulate the transport activity of P-glycoprotein (P-gp) and apoptosis induction on the L5178 mouse lymphoma cell line containing the human MDR1 gene was studied by flow cytometry. The reversal of multidrug-resistance (MDR) was investigated by measuring the accumulation of rhodamine-123, a fluorescent substrate analog of doxorubicin, in cancer cells. Verapamil was applied as a positive control. For the evaluation of the compounds as apoptosis inducers, tumor cells were stained with FITC-labelled annexin-V and propidium iodide. The tetramethylated derivative (2) was found to be a powerful inhibitor of P-gp activity. Compounds 1 and 2 showed an increased apoptotic effect in the MDR subline, the most active being piceatannol (1). Furthermore, in the combination chemotherapy model, the interaction between doxorubicin and the resistance modifier 2 was studied in vitro. The results of checkerboard experiments indicated that the type of interaction was additive between doxorubicin and compound 2 on the human MDR1 gene-transfected mouse lymphoma cells. However, in the MCF7/dox human breast cancer cells, the interaction was non-additive. The degree of additive and non-additive interactions were close to the borderline of the FIX values corresponding to the two types of interactions.

  • Stilbenes
  • Euphorbia lagascae
  • multidrug resistance
  • apoptosis

Footnotes

  • Received March 15, 2006.
  • Accepted July 7, 2006.
  • Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved
PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 26, Issue 5A
September-October 2006
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Interaction between Doxorubicin and the Resistance Modifier Stilbene on Multidrug Resistant Mouse Lymphoma and Human Breast Cancer Cells
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
5 + 12 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Interaction between Doxorubicin and the Resistance Modifier Stilbene on Multidrug Resistant Mouse Lymphoma and Human Breast Cancer Cells
MARIA-JOSÉ U. FERREIRA, NOÉLIA DUARTE, NORA GYÉMÁNT, RITA RADICS, GEORGY CHEREPNEV, ANDRAS VARGA, JOSEPH MOLNÁR
Anticancer Research Sep 2006, 26 (5A) 3541-3546;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Interaction between Doxorubicin and the Resistance Modifier Stilbene on Multidrug Resistant Mouse Lymphoma and Human Breast Cancer Cells
MARIA-JOSÉ U. FERREIRA, NOÉLIA DUARTE, NORA GYÉMÁNT, RITA RADICS, GEORGY CHEREPNEV, ANDRAS VARGA, JOSEPH MOLNÁR
Anticancer Research Sep 2006, 26 (5A) 3541-3546;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Biological Activity of Hydantoin Derivatives on P-Glycoprotein (ABCB1) of Mouse Lymphoma Cells
  • Stilbenes as Multidrug Resistance Modulators and Apoptosis Inducers in Human Adenocarcinoma Cells
  • Screening of Some Saponins and Phenolic Components of Tribulus terrestris and Smilax excelsa as MDR Modulators
  • Google Scholar

More in this TOC Section

  • Dual Role of PSMB9 Linking Immune Activation and Tumor Adaptation in Hepatocellular Carcinoma With Therapeutic and Prognostic Implications
  • CD133+ Lung Cancer Stem-like Cells Resist Plasma-activated Medium Through PRDX5-mediated Antioxidant Defense
  • Iodine-Hoechst Enhances X-ray Sensitivity of Cancer Cells Under Normal and Low Oxygen Conditions
Show more Experimental Studies
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire